Moderna is trying to find a path to profitability in the wake of disappointing vaccine sales. In September, the company said ...

The revelation aired during Vance's interview on Joe Rogan's podcast episode with the potential next vice president.

Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most ...

Yes, older Americans should get yet another COVID shot—but if you have already gotten the latest version, there's no rush.

It is understood that Health Secretary Wes Streeting is considering plans to set up a programme to compensate those who have ...

Microsoft billionaire Bill Gates is set to stand trial in the Netherlands for allegedly misleading the public about the ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

The Ministry of Health has approved Moderna's updated COVID vaccines, which target the new JN1 variant of the virus.

For the Pfizer/BioNTech and Moderna vaccines, this means that small changes ... swelling and redness at the injection site; tiredness; headache; muscle pain; chills; and fever.

To date, no vaccines that protect NoV have been licensed. Credit: Novikov Aleksey via Shutterstock. At IDWeek 2024, Moderna presented interim results ... with most participants receiving two ...